Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 696 results

Media Release / Jan 23, 2013

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Media Release / Dec 19, 2012

NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis

- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11- SJIA patients treated…
Media Release / Dec 19, 2012

NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
Media Release / Dec 15, 2012

Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder

- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
Media Release / Dec 15, 2012

Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Media Release / Dec 15, 2012

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder

- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
Media Release / Dec 14, 2012

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Media Release / Nov 07, 2012

Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure

RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and was therefore positive under pre-specified criteriaNewly presented data show that at six months,…
Media Release / Nov 07, 2012

Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
Media Release / Oct 16, 2012

Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com

- Leeza and family share highs, lows and insights about caring for her mother with Alzheimer's disease in new video series- Ten national contest winners recognized for words of wisdom about finding…

‹ Previous page
1
…
55
56
57
58
59
60
61
…
70
› Next page